Schroder Investment Management Group trimmed its position in Exelixis, Inc. (NASDAQ:EXEL) by 40.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 12,167 shares of the biotechnology company’s stock after selling 8,109 shares during the period. Schroder Investment Management Group’s holdings in Exelixis were worth $260,000 at the end of the most recent quarter.
Other large investors have also recently made changes to their positions in the company. Wells Fargo & Company MN raised its position in shares of Exelixis by 320.7% in the 1st quarter. Wells Fargo & Company MN now owns 3,204,443 shares of the biotechnology company’s stock valued at $76,266,000 after acquiring an additional 2,442,773 shares during the period. U S Global Investors Inc. raised its position in shares of Exelixis by 139.1% in the 2nd quarter. U S Global Investors Inc. now owns 53,359 shares of the biotechnology company’s stock valued at $1,140,000 after acquiring an additional 31,047 shares during the period. Janus Henderson Group PLC raised its holdings in Exelixis by 390.8% during the 2nd quarter. Janus Henderson Group PLC now owns 159,966 shares of the biotechnology company’s stock worth $3,418,000 after buying an additional 127,372 shares during the period. First Mercantile Trust Co. raised its holdings in Exelixis by 10.9% during the 2nd quarter. First Mercantile Trust Co. now owns 6,386 shares of the biotechnology company’s stock worth $136,000 after buying an additional 627 shares during the period. Finally, First Trust Advisors LP raised its holdings in Exelixis by 8.0% during the 2nd quarter. First Trust Advisors LP now owns 5,865,637 shares of the biotechnology company’s stock worth $125,349,000 after buying an additional 433,202 shares during the period. Institutional investors and hedge funds own 77.39% of the company’s stock.
In other Exelixis news, Director George Poste sold 20,000 shares of the firm’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $20.60, for a total transaction of $412,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael Morrissey sold 34,721 shares of the firm’s stock in a transaction on Wednesday, July 17th. The shares were sold at an average price of $21.37, for a total value of $741,987.77. The disclosure for this sale can be found here. Insiders sold 360,028 shares of company stock valued at $7,298,351 over the last three months. 4.50% of the stock is owned by company insiders.
Shares of NASDAQ:EXEL traded down $0.79 during midday trading on Friday, hitting $17.14. The stock had a trading volume of 417,373 shares, compared to its average volume of 2,360,178. Exelixis, Inc. has a 12 month low of $13.42 and a 12 month high of $25.31. The company has a quick ratio of 8.53, a current ratio of 8.64 and a debt-to-equity ratio of 0.02. The business’s 50-day simple moving average is $19.55 and its 200-day simple moving average is $20.81. The company has a market cap of $5.43 billion, a P/E ratio of 11.99 and a beta of 1.81.
Exelixis (NASDAQ:EXEL) last released its earnings results on Wednesday, July 31st. The biotechnology company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.02. Exelixis had a net margin of 70.52% and a return on equity of 31.31%. The business had revenue of $240.28 million during the quarter, compared to analysts’ expectations of $226.97 million. During the same period last year, the business earned $0.31 earnings per share. The firm’s revenue was up 29.1% on a year-over-year basis. As a group, equities analysts predict that Exelixis, Inc. will post 0.92 earnings per share for the current year.
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Read More: Investing in Blue-Chip Stocks
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.